A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Conditions
- Colitis, Ulcerative
- Interventions
- Drug: Matching Placebo
- Registration Number
- NCT04630028
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics \[PK\]) in pediatric participants with moderately to severely active UC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 112
- Medically stable on the basis of physical examination, medical history, and vital signs, performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and acknowledged by the investigator
- Must have had UC diagnosed prior to screening
- Have moderately to severely active UC, defined as a baseline Mayo score of 6 through 12, inclusive, with a screening Mayo endoscopy subscore greater than or equal to (>=) 2 as determined by a central review of the video of the endoscopy
- A participant who has had extensive colitis for >= 8 years, or disease limited to the left side of the colon for >= 10 years, must: a) have had a full colonoscopy to assess for the presence of dysplasia within 1 year before the first administration of study intervention or b) have a full colonoscopy with surveillance for dysplasia as the baseline endoscopy during the screening period. Results from these surveillance biopsies must be negative for dysplasia (low-grade, high-grade, or indeterminant) prior to the first administration of study intervention
- Females of childbearing potential must have a negative highly sensitive urine pregnancy test at screening and at Week I-0 prior to study intervention administration
- Have UC limited to the rectum only or to less than (<) 20 centimeter (cm) of the colon
- Presence or history of colonic or small bowel obstruction within 6 months prior to screening, confirmed by objective radiographic or endoscopic evidence of a stricture with resulting obstruction (dilation of the colon or small bowel proximal to the stricture on barium radiograph or an inability to traverse the stricture at endoscopy)
- Have a history of latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis, or have had a nontuberculous mycobacterial infection prior to screening
- Presence or history of any malignancy including presence or history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (example, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic areas) and monoclonal gammopathy of undetermined significance, or clinically significant hepatomegaly or splenomegaly
- Has known allergies, hypersensitivity, or intolerance to ustekinumab or its excipients
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Maintenance (M) Period: Ustekinumab once every 12 Week (q12w) Ustekinumab Dose Based on BSA and Body Weight Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind. Induction Period (I): Ustekinumab Ustekinumab Dose Based on BSA and Body Weight All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square \[mg/m\^2\]) or weight-tiered induction dose (milligram per kilogram \[mg/kg\]). Maintenance (M) Period: Ustekinumab once every 8 Week (q8w) Ustekinumab Dose Based on BSA and Body Weight Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind. Maintenance (M) Period: Ustekinumab once every 8 Week (q8w) Matching Placebo Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind. Maintenance (M) Period: Ustekinumab once every 12 Week (q12w) Matching Placebo Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m\^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
- Primary Outcome Measures
Name Time Method Serum Concentration of Ustekinumab Up to 74 weeks Serum samples will be analyzed to determine concentrations of ustekinumab.
Number of Participants with Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability Up to 74 weeks SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, and suspects transmission of any infectious agent via a medicinal product.
Number of Participants with AEs Leading to Discontinuation of Study Intervention Up to 74 weeks Number of Participants with discontinuation of study intervention due to an AE, infections, injection-site reactions, and AEs during or within 1 hour of an infusion will be reported.
Number of Participants with AEs of Special Interest (AESI) as a Measure of Safety and Tolerability Up to 74 weeks AESI of any newly identified malignancy, case of active tuberculosis (TB), or opportunistic infection occurring after the first administration of study intervention(s) in participants will be reported.
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability Up to 74 weeks An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Number of Participants with Laboratory Abnormalities Up to 74 weeks Number of participants with laboratory abnormalities related to hematology, serum chemistry, and coagulation will be reported.
Reactions Temporally Associated with an Intravenous (IV) Infusion and Subcutaneous (SC) Injection-site Reactions Up to 74 weeks Reactions temporally associated with an IV infusion (induction period) and SC injection-site reactions (maintenance period) will be reported.
US Specific: Clinical Remission at M-44 for Participants who are in Clinical Response at I-8 Week 52 Clinical remission at M-44 for participants who are in clinical response at I-8 will be reported. Clinical remission is defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
Global: Number of Participants with Clinical Remission at Induction Week 8 (I-8) Visit Week 8 Clinical remission is defined as Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
- Secondary Outcome Measures
Name Time Method Endoscopic Improvement at I-8 Visit Week 8 Endoscopic improvement is defined as a Mayo endoscopy subscore of 0 or \<= 1 with no friability present on the endoscopy.
Number of Participants with Symptomatic Remission at M-44 Visit Week 52 Symptomatic remission is defined as Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.
Number of Participants With Clinical Response at I-8 Visit Week 8 Clinical response is defined as decrease from baseline in the modified Mayo score by \>= 30 percent (%) and \>=2 points, with either a decrease from baseline in the rectal bleeding subscore of \>= 1 or a rectal bleeding subscore of 0 or 1.
Number of Participants with Symptomatic Remission at I-8 Visit Week 8 Symptomatic remission is defined as Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0, where the stool frequency subscore has not increased from induction baseline.
Histologic-endoscopic Mucosal Improvement at Week I-8 Week 8 Histologic-endoscopic mucosal improvement is defined as achieving a combination of histologic (neutrophil infiltration in less than \[\<\] 5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system) and endoscopic improvement (endoscopy subscore of 0 or 1 with no friability present on the endoscopy).
Clinical Remission at M-44 as Assessed by the PUCAI Score Week 52 Clinical remission is defined as a PUCAI score less than \< 10.
Clinical Remission at M-44 and not Receiving Corticosteroids for at Least 90 Days Prior to M-44 Among Participants who Received Corticosteroids at M-0 Week 52 Clinical remission is defined as a PUCAI score less than \< 10. Clinical remission at M-44 and in participants not receiving corticosteroids for at least 90 days prior to M-44 among participants who received corticosteroids at M-0 as assessed by PUCAI score will be reported.
Clinical Remission at I-8 as Assessed by the Pediatric Ulcerative Colitis Activity Index Score (PUCAI) Score Week 8 Clinical remission is defined as a PUCAI score less than (\<)10.
Clinical Remission at M-44 for Participants who are in Clinical Remission at I-8 Week 52 Clinical remission at M-44 for participants who are in clinical remission at I-8 will be reported. Clinical remission is defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
Histologic-endoscopic Mucosal Improvement at Week M-44 Week 52 Histologic-endoscopic mucosal improvement is defined as achieving a combination of histologic (neutrophil infiltration in \< 5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system) and endoscopic improvement (endoscopy subscore of 0 or 1 with no friability present on the endoscopy).
Number of Participants with Clinical Remission at Week 44 (M-44) Visit Week 52 Clinical remission is defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
Endoscopic Improvement at M-44 Visit Week 52 Endoscopic improvement is defined as a Mayo endoscopy subscore of 0 or \<= 1 with no friability present on the endoscopy.
Corticosteroid-free Clinical Remission at Week M-44 Week 52 Corticosteroid-free clinical remission is defined as a Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline; and not receiving corticosteroids for at least 90 days prior to Week M-44.
US Specific: Number of Participants with Clinical Remission at I-8 Visit Week 8 Clinical remission is defined as Mayo stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1 with no friability present on the endoscopy, where the stool frequency subscore has not increased from induction baseline.
Trial Locations
- Locations (58)
WIP Warsaw IBD Point Profesor Kierkus
🇵🇱Warszawa, Poland
Nemours DuPont Hospital for Children
🇺🇸Wilmington, Delaware, United States
Children's Center for Digestive Health Care
🇺🇸Atlanta, Georgia, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Morristown Memorial Hospital
🇺🇸Morristown, New Jersey, United States
Levine Childrens at Atrium Health
🇺🇸Charlotte, North Carolina, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Penn State Hershey Children's Hospital
🇺🇸Hershey, Pennsylvania, United States
Cook Childrens Medical Center
🇺🇸Fort Worth, Texas, United States
Pediatric Specialists Of Virginia
🇺🇸Fairfax, Virginia, United States
Scroll for more (48 remaining)WIP Warsaw IBD Point Profesor Kierkus🇵🇱Warszawa, Poland